DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Viridian Announces Positive Data From Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients With Thyroid Eye Disease (TED)
Viridian Therapeutics, Inc., a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced positive topline clinical data from the first two cohorts in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). TED is a rare autoimmune disease in which the body’s own immune system attacks the tissues around and behind the eyes causing inflammation, swelling, and damage that develops into debilitating signs and symptoms including double vision, bulging eyes, and ocular pain.
“These additional Phase 1/2 clinical data continue to support the potential for VRDN-001 to be a new treatment option for patients suffering from TED,” said Raymond Douglas, M.D., Ph.D., director of the Orbital and Thyroid Eye Disease Program, Cedars-Sinai Medical Center and an investigator on the VRDN-001 trial.
Evidence & EducationEffects of Selenium on Short-Term Control of Hyperthyroidism due to Graves’ Disease Treated With Methimazole: ...Objective: In spite of previous conflic...
Evidence & EducationRisk Factors of Hepatic Dysfunction in Patients With Graves’ Hyperthyroidism and the Efficacy of 131iodine Tre...Hepatic dysfunction is often observed in...
Evidence & EducationFor Parents: Hyperthyroidism and Graves’ DiseaseWhat is the Thyroid? The thyroid is a s...
Evidence & EducationStress Triggers the Onset and the Recurrences of Hyperthyroidism in Patients With Graves’ DiseaseThe aim of this study was to evaluate th...
People & PlacesMaria Albuja-Cruz, MDMaria Albuja-Cruz is an Associate Profes...
People & PlacesJacqueline T. Kung, MDJacqueline T. Kung is the Director of Th...
Evidence & EducationEffects of Treatment Modalities for Graves’ Hyperthyroidism on Graves’ Orbitopathy: A 2015 Italian Society of En...Graves’ disease is the most frequent f...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.